Modified saccharides
AssigneeGlaxosmithkline Biologicals SA
InventorsAngela Bardotti, Francesco Berti, Paolo Costantino
Life of this patent
Estimating the term…
Loading patent…
AssigneeGlaxosmithkline Biologicals SA
InventorsAngela Bardotti, Francesco Berti, Paolo Costantino
Estimating the term…
Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.
A saccharide-protein conjugate, wherein the saccharide is a modified Neisseria meningitidis serogroup A capsular saccharide wherein at least 90% of the hydroxyl groups at position 3 and at least 90% of the hydroxyl groups at position 4 of the monosaccharide units of the saccharide comprise a blocking group of the formula (Ia):
A molecule comprising a saccharide moiety of formula:
Dependencies are inferred from the claim text.